In vitro evaluation of CAR-T cells in patient-derived glioblastoma models Academic Article uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • Advances in chimeric antigen receptor (CAR) T cell therapies have led to the modality dominating translational cancer research; however, a standardized protocol for evaluating such therapies in vitro is needed. This protocol details the in vitro preclinical evaluation of CAR-T cell therapies for glioblastoma (GBM), including target cell cytotoxicity and T cell proliferation, activation, and cytokine release assays. For complete details on the use and execution of this protocol, please refer to Vora et al. (2020).


  • Brakel, Benjamin A
  • Chokshi, Chirayu R
  • Salim, Sabra K
  • Venugopal, Chitra
  • Singh, Sheila

publication date

  • December 2021